<DOC>
	<DOCNO>NCT01953341</DOCNO>
	<brief_summary>The primary purpose study determine whether AMG 333 safe well tolerate healthy subject subject migraine . As part secondary objective , study characterize pharmacokinetic ( PK ) profile AMG 333 , well characterize effect AMG 333 cold pressor test ( CPT ) -induced increase blood pressure single oral dos healthy subject subject migraine</brief_summary>
	<brief_title>Single-Ascending Dose Study AMG 333 Healthy Subjects Subjects With Migraines</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , ascend single-dose study evaluate AMG 333 healthy subject subject migraine . The study consist 8 cohort : 7 cohort healthy subject 1 cohort subject migraine . For cohort 1 7 , 8 subject enrol , subject randomize 6 subject receive AMG 333 2 subject receive placebo ( 3:1 ratio ) . In cohort 8 , 24 subject migraine enrol , depend enrollment rate emerge safety tolerability data . These migraine subject randomize receive AMG 333 placebo crossover fashion . Both healthy migraine subject monitor house 4 day allow return home remainder 14 day observation period . Both healthy migraine subject keep headache diary .</detailed_description>
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Healthy male female subject without migraine ≥18 ≤55 year age time screening , history evidence clinically relevant medical disorder determine investigator consultation Amgen physician . History evidence clinically significant disorder , condition , disease , opinion investigator Amgen physician , would significantly impair pain perception ( eg , history stroke , history neuropathy ) interfere evaluation , procedure , study completion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Migraine</keyword>
</DOC>